进行性产前外显子组测序路径中胎儿表型的演变及临床影响:队列研究
该回顾性队列分析纳入54例有胎儿结构异常且染色体微阵列正常的病例,比较PAGE路径与NHS England R21路径的产前三人外显子组测序。R21路径诊断率55.2%(16/29)高于PAGE路径28.0%(7/25)(P=0.04),平均周转时间分别为14.2天与54.0天。检出致病性变异对78.3%(18/23)病例有显著临床影响。
要点
- R21路径诊断率55.2%(16/29)高于PAGE路径28.0%(7/25)(P=0.04)。
- R21路径平均周转时间14.2天(范围3-29天),PAGE路径54.0天(范围14-213天)。
- 检出致病性变异对78.3%(18/23)病例有显著临床影响,最常影响妊娠进程和新生儿管理决策(7/18,38.9%)。
核心结论
- 产前外显子组测序采用NHS England R21路径在该队列中显示出很大前景,使超过半数经预先选择的超声胎儿结构异常病例获得遗传学诊断。
- 监测并实时更新胎儿表型以及基于产后发现重新分类变异,对于提高该新兴基因组技术已显现的临床影响至关重要。
研究设计与样本
- 回顾性队列分析,前瞻性收集的胎儿病例,在英国伯明翰West Midlands Regional Genetics Laboratory进行三人外显子组测序,纳入标准为存在结构异常且染色体微阵列检测正常。
- 研究分两阶段:2018年7月至2020年10月采用PAGE研究临床路径,基于1542个发育障碍基因面板并由多学科团队选择病例。
- 2020年10月至2021年7月采用NHS England R21路径,具有明确纳入标准和1205个产前相关基因面板。
- 整个妊娠期及产后进行深度表型分析。
- 共纳入54例病例。
主要发现
- R21路径实施前诊断率为28.0%(7/25),实施后为55.2%(16/29)(P=0.04)。
- R21路径实施前平均周转时间为54.0天(范围14-213天),实施后为14.2天(范围3-29天)。
- 在检出致病性变异且妊娠进入第三孕期的病例中,73.3%(11/15)在第二至第三孕期之间检出额外异常,主要继发于进行性水肿特征(3/11,27.3%)、关节挛缩(3/11,27.3%)或脑部异常(2/11,18.2%)。
- 3例意义不明变异基于产后信息重新分类为可能致病性。
- 检出致病性变异对78.3%(18/23)病例有显著临床影响,最常影响妊娠进程和新生儿管理决策(7/18,38.9%)。
临床怎么用
- 原文结论指出产前外显子组测序采用NHS England R21路径在该队列中显示出很大前景。
- 原文结论强调监测并实时更新胎儿表型以及基于产后发现重新分类变异对于提高临床影响至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine (1) the diagnostic yield and turnaround time (TAT) of two consecutive prenatal exome sequencing (ES) pathways, (2) the evolution of the fetal phenotype and (3) the clinical impact of detecting causative pathogenic variants and incidental findings. METHODS: This was a retrospective cohort analysis of prospectively collected fetal cases that underwent trio ES in the presence of a structural anomaly and normal chromosomal microarray testing in the West Midlands Regional Genetics Laboratory, Birmingham, UK. The study included two phases: (1) between July 2018 and October 2020, the clinical pathway from the Prenatal Assessment of Genomes and Exomes (PAGE) study was adopted and involved prenatal trio ES based on a panel of 1542 development disorder genes and case selection by a multidisciplinary team; (2) between October 2020 and July 2021, prenatal trio ES investigation was based on the National Health Service (NHS) England R21 pathway, with definitive inclusion criteria and a panel of 1205 prenatally relevant genes. Deep phenotyping was performed throughout pregnancy and postnatally. RESULTS: A total of 54 cases were included. The diagnostic yield before vs after R21 pathway implementation was 28.0% (7/25) and 55.2% (16/29), respectively (P = 0.04). The respective values for mean TAT were 54.0 days (range, 14-213 days) and 14.2 days (range, 3-29 days). In cases in which a causative pathogenic variant was identified and in which the pregnancy reached the third trimester, additional anomalies were detected between the second and third trimesters in 73.3% (11/15) of cases, predominantly secondary to progressive hydropic features (3/11 (27.3%)), arthrogryposis (3/11 (27.3%)) or brain anomaly (2/11 (18.2%)). In three cases, a variant of uncertain significance was reclassified to likely pathogenic based on postnatal information. Detection of a causative pathogenic variant had a significant clinical impact in 78.3% (18/23) of cases, most frequently affecting decision-making regarding the course of the pregnancy and neonatal management (7/18 (38.9%)). CONCLUSIONS: Prenatal ES using the NHS England R21 pathway showed great promise when applied to this cohort, allowing a genetic diagnosis to be made in over half of preselected cases with a fetal structural anomaly on ultrasound. Monitoring and real-time updating of fetal phenotype and reclassification of variants based on postnatal findings is vital to increase the clinical impact that is already evident from this emerging genomic technology. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Mone F, Abu Subieh H, Doyle S, et al. Evolving fetal phenotypes and clinical impact of progressive prenatal exome sequencing pathways: cohort study. Ultrasound Obstet Gynecol. 2022. PMID: 34940998. doi:10.1002/uog.24842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。